Glycogen Synthase Kinase 3beta Phosphorylates Tau at Both Primed and Unprimed Sites

DIFFERENTIAL IMPACT ON MICROTUBULE BINDING*

Jae-Hyeon ChoDagger and Gail V. W. Johnson§

From the Department of Psychiatry, University of Alabama at Birmingham, Birmingham, Alabama 35294-0017

Received for publication, June 22, 2002, and in revised form, October 2, 2002

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Glycogen synthase kinase 3beta (GSK3beta ) phosphorylates substrates, including the microtubule-associated protein tau, at both primed and unprimed epitopes. GSK3beta phosphorylation of tau negatively regulates tau-microtubule interactions; however the differential effects of phosphorylation at primed and unprimed epitopes on tau is unknown. To examine the phosphorylation of tau at primed and unprimed epitopes and how this impacts tau function, the R96A mutant of GSK3beta was used, a mutation that prevents phosphorylation of substrates at primed sites. Both GSK3beta and GSK3beta -R96A phosphorylated tau efficiently in situ. However, expression of GSK3beta -R96A resulted in significantly less phosphorylation of tau at primed sites compared with GSK3beta . Conversely, GSK3beta -R96A phosphorylated unprimed tau sites to a significantly greater extent than GSK3beta . Prephosphorylating tau with cdk5/p25 impaired the ability of GSK3beta -R96A to phosphorylate tau, whereas GSK3beta -R96A phosphorylated recombinant tau to a significantly greater extent than GSK3beta . Moreover, the amount of tau associated with microtubules was reduced by overexpression of GSK3beta but only when tau was phosphorylated at primed sites, as phosphorylation of tau by GSK3beta -R96A did not negatively regulate the association of tau with microtubules. These results demonstrate that GSK3beta -mediated phosphorylation of tau at primed sites plays a more significant role in regulating the interaction of tau with microtubules than phosphorylation at unprimed epitopes.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Tau is a family of microtubule-associated proteins that are expressed predominantly in neurons and are produced by alternative splicing of a single gene (1, 2). Although tau likely plays a role in numerous neuronal processes, such as vesicle transport (3, 4), microtubule-plasma membrane interactions (5, 6), and the intracellular localization of protein such as fyn (7, 8), 14-3-3 (9, 10), and protein phosphatase 2A (11, 12), the best characterized function of tau is the binding and stabilization of microtubules (13-15). Tau is a phosphoprotein, and in vitro, numerous studies have demonstrated that site-specific phosphorylation of tau regulates its ability to bind and stabilize microtubules. Increased phosphorylation of tau in situ tends to negatively regulate tau-microtubule interactions (16-20), although the effects of site-specific tau phosphorylation on microtubule binding in the cell have not been as thoroughly studied, as they have been in vitro.

Numerous protein kinases phosphorylate tau in vitro; however in situ the list is much more abbreviated. Protein kinase A (21), microtubule affinity regulating kinases (22), cyclin-dependent protein kinase 5 (cdk5)1/p35[p25] (23, 24), and glycogen synthase kinase 3beta (GSK3beta ) (25-29) have been shown to phosphorylate tau in situ. Although all these kinases can phosphorylate tau in situ, there is emerging evidence that GSK3beta may play a major role in regulating tau phosphorylation both in physiological and pathological conditions.

GSK3beta is expressed ubiquitously and found at high levels in brain where it localizes predominantly to neurons (30). GSK3beta is a critically important protein kinase in brain as it phosphorylates a number of important substrates including transcription factors such as beta -catenin, cAMP-response element-binding protein, and cytoskeletal proteins such as MAP1B and tau, which regulates their function (31). Although numerous GSK3beta substrates have been identified, the consensus sites recognized by GSK3beta are not straightforward. GSK3beta can phosphorylate unprimed sites at Ser/Thr-Pro motifs. Examples of unprimed substrates are axin and adenomatous polyposis coli gene product (APC) (32-34). In other cases the substrate must first be phosphorylated at a site that is four amino acids C-terminal to the target site, which primes the substrate for phosphorylation by GSK3beta . This primed motif ((S/T)XXX(S/T)[P]) often occurs in proline-rich regions of the substrate (32, 35). Glycogen synthase (36), eukaryotic protein synthesis initiation factor 2B (37), and beta -catenin (38) are all primed substrates. Indeed, it appears as if the majority of GSK3beta substrates are actually primed (35). Interestingly, although GSK3beta phosphorylates tau at unprimed sites (39, 40), prior phosphorylation by cdk5/p25[p25] enhances the phosphorylation of tau at specific sites (e.g. Thr-231) (41, 42), indicating that tau may be both a primed and unprimed substrate of GSK3beta .

GSK3beta activity is regulated by its phosphorylation state. Phosphorylation of GSK3beta on Tyr-216 increases its activity (43), and phosphorylation at Ser-9 inhibits kinase activity (44, 45), and both these events are regulated by growth factor signaling (31). In response to insulin or insulin-like growth factor, Akt is activated, and this kinase phosphorylates GSK3beta on Ser-9 decreasing its activity (46). Recently, it was demonstrated that phosphorylation of Ser-9 results in the N-terminal of GSK3beta acting as a pseudosubstrate, occupying the same binding site used by primed substrates (32, 44, 47). It was also found that Arg-96 in GSK3beta is critically important in forming the binding pocket for the phosphate group of the primed substrates (or pseudosubstrate) (32, 44, 47). Mutation of Arg-96 to Ala decreased the ability of GSK3beta to phosphorylate primed substrates significantly but had no effect on its ability to phosphorylate unprimed sites (32).

Although there are data to suggest that tau is both a primed and unprimed substrate of GSK3beta in situ, this has not been demonstrated clearly. Further, how phosphorylation of tau by GSK3beta on different sites modulates its association with microtubules has not been explored thoroughly. By using wild type GSK3beta and GSK3beta with the R96A or S9A mutation we demonstrate that GSK3beta phosphorylates tau at both primed sites (pThr-231) and unprimed sites (pSer-396/404). Disruption of the GSK3beta phosphate-binding pocket (R96A mutation) results in a significant decrease in tau phosphorylation at the primed site of Thr-231 and an enhancement of phosphorylation at the unprimed site of Ser-396/404. Further, GSK3beta -R96A phosphorylates recombinant tau to a significantly greater extent than wild type or GSK3beta -S9A; however if tau is first phosphorylated by cdk5/p25 then GSK3beta -R96A is significantly less effective than wild type or GSK3beta -S9A in phosphorylating tau. Finally, GSK3beta -mediated phosphorylation of tau at only the primed sites decreases tau-microtubule interactions.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Cell Culture-- CHO cells were grown in F-12 medium supplemented with 5% fetal bovine serum (Cyclone), 20 mM L-glutamine (Invitrogen), 10 units/ml penicillin (Invitrogen), and 100 units/ml streptomycin (Invitrogen). Cells were used at a confluency of 50-80% for all experiments.

Plasmid Constructs-- The wild type tau (4R-Tau; +exon 10, -exons 2 and 3) construct was a generous gift from Dr. M. Hutton (Mayo Clinic, Jacksonville, FL). 4R-Tau was subcloned into mammalian expression vector, pCDNA 3.1(-) (Invitrogen). By using the wild type tau construct as a template, PCR was performed (forward primer, 5'-GCC GAA TTC TAT GGC TGA GCC CCG CCA G-3'; reverse primer, 5'-CGG GGT ACC TCA CAA ACC CTG CTT GGC-3'), and the PCR reaction product was digested with EcoRI and KpnI and ligated into the EcoRI and KpnI sites of the pCDNA 3.1(-). The integrity of the 4R-tau construct was confirmed by sequence analysis.

The cytomegalovirus expression vectors for p25 and cdk5 were generous gifts from Dr L.-H. Tsai (24). The cdk5 insert was subcloned into the BamHI site of pcDNA3.1(+) (48). The wild type HA-GSK3beta was a generous gift from Dr. J. Woodgett (Ontario Cancer Institute). To generate HA-GSK3beta -S9A and HA-GSK3beta -R96A site-directed mutagenesis using the QuikChangeTM site-directed mutagenesis kit (Stratagene) was carried out with the following primer pairs: HA-GSK3beta -S9A, forward primer, 5'-GCT CTC CGC AAA GGC GGT TCT GGG C-3'; reverse primer, 5'-GCC CAG AAC CAC CGC CTT TGC GGA GAG C-3'; HA-GSK3beta -R96A, forward primer, 5'-GAC AAG AGA TTT AAG AAT GCA GAG CTC CAG ATC ATG-3'; reverse primer, 5'-CAT GAT CTG GAG CTC TGC ATT CTT AAA TCT CTT GTC-3'. Mutations were verified by DNA sequence analysis.

Transient Transfections-- 4R-Tau, wild type HA-GSK3beta , HA-GSK3beta -S9A, or HA-GSKbeta -R96A were transiently transfected into CHO cells using FuGENE 6 (Roche Molecular Biochemicals) transfection reagent according to the manufacturer's protocol. 36 h after transfection, the cells were washed with ice-cold phosphate-buffered saline and then collected and processed as described below for the different assays.

Immunoblotting-- Cells were collected in lysis buffer (150 mM NaCl, 10 mM Tris-HCl, 1 mM EGTA, 1 mM EDTA, 0.2 mM sodium vanadate, 0.5% Nonidet P-40), containing 1 mM phenylmethylsulfonyl fluoride, 0.1 µM okadaic acid, and a 10 µg/ml concentration each of aprotinin, leupeptin, and pepstatin. Lysates were sonicated on ice and centrifuged, and protein concentrations in the supernatants were determined using the bicinchoninic acid assay (Pierce). Equal amounts of protein from each sample were electrophoresed on 10% SDS-polyacrylamide gels, transferred to nitrocellulose, and probed with the indicated antibodies. The tau antibodies used in this study were Tau5/5A6 (Tau5 from Dr. L. Binder), which are phospho-independent tau antibodies (49-51), AT180 (Innogenetics), which recognizes tau when it is phosphorylated at Thr-231 (52, 53), and PHF-1 (from Dr. P. Davies), which recognizes tau phosphorylated at Ser-396/404 (54). The monoclonal GSK3beta was purchased from Transduction Laboratories, the monoclonal cdk5 antibody was from Santa Cruz Biotechnology, the monoclonal beta -tubulin antibody was from Sigma, the monoclonal beta -actin antibody was from Chemicon, and the monoclonal HA antibody was from Roche Molecular Biochemicals. After incubation with the appropriate horseradish peroxidase-conjugated secondary antibody (Jackson ImmunoResearch Laboratories), the blots were developed using enhanced chemiluminescence (Amersham Biosciences).

Preparation of Primed Recombinant Tau-- To prephosphorylate (prime) tau to use as a GSK3beta substrate, cdk5 and p25 were co-expressed in CHO cells, and cdk5 was immunoprecipitated. 120 µg of the protein extract (1 µg/µl) was incubated with 2 µl of rabbit polyclonal anti-cdk5 antibody (Santa Cruz Biotechnology) overnight at 4 °C with gentle agitation. Extracts were then incubated with 40 µl of washed protein A-Sepharose (Sigma) for 2 h at 4 °C. The phosphorylation reaction was carried out by mixing immunoprecipitated cdk5/p25 with 40 µl of kinase buffer containing 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 250 µM ATP, and 0.2 µg/µl recombinant tau protein (Takara/Panvera, Madison, WI). For the negative control, the reaction was performed without ATP in the kinase buffer. The samples were incubated at 30 °C for 30 min with shaking and then spun to pellet the cdk5/p25 immune complex. The supernatants containing the recombinant tau were collected and dialyzed to remove free ATP using Slide-A-Lyzer mini dialysis units (Pierce). Following dialysis, protein concentrations were determined by using the bicinchoninic acid assay. The supernatants were immunoblotted for cdk5 to confirm that there was no cdk5 present.

Measurement of GSK3beta Activity-- To immunoprecipitate the HA-GSK3beta constructs, 70 µg of protein from cellular extracts (1 µg/µl) prepared in lysis buffer was incubated with 2 µl of mouse monoclonal HA antibody overnight at 4 °C with gentle agitation. Extracts were then incubated with 30 µl of washed protein G-Sepharose (Sigma) for 2 h at 4 °C. The immobilized immune complexes were washed twice with lysis buffer and twice with kinase buffer (20 mM Tris, pH 7.5, 5 mM MgCl2, and 1 mM dithiothreitol). Kinase activity was measured by mixing immunoprecipitated GSK3beta with 30 µl of kinase buffer containing 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 250 µM ATP, 1.4 µCi of [gamma -32P]ATP (Amersham Biosciences), and 0.1 µg/µl recombinant tau protein (in some experiments prephosphorylated tau was used). The samples were incubated at 30 °C for 30 min, and 30 µl of 2× SDS stop buffer was added to each sample to stop the reaction. Samples were placed in a boiling water bath for 5 min, and proteins were separated on 10% SDS-polyacrylamide gels. The gels were vacuum-dried, exposed to a phosphoscreen overnight, and quantitated using a PhosphorImager (Molecular Dynamics, Sunnyvale, CA). The efficiency of HA immunoprecipitation was determined by immunoblotting for GSK3beta .

In indicated experiments, the activity of GSK3beta was measured using a primed peptide substrate, phosphoglycogen synthase peptide-2 (Upstate Biotechnology) as described previously (55), except that the peptide concentration used was 25 µM, and the reaction time was 20 min. A volume of 10 µl of the 30-µl reaction mixture was then spotted in triplicate on P81 filter paper (Whatman). The filters were washed three times with 0.5% phosphoric acid for 15 min each and one time with 95% ethanol for 15 min and dried, and 32P incorporation into the peptide was measured by scintillation counting.

Fractionation-- Cell were rinsed once with warm phosphate-buffered saline and once with warm extraction buffer (80 mM PIPES, pH 6.8, 1.0 mM MgCl2, 2.0 mM EGTA, 30% glycerol, 10 mM benzamidine, 50 µg/ml leupeptin, 1.0 mM phenylmethylsulfonyl fluoride, and 0.5 µM okadaic acid). Cells were then incubated in 300 µl (for a 60-mm plate) of extraction buffer containing 0.1% Triton X-100 for 10 min at 37 °C. Cells were transferred into microcentrifuge tubes and centrifuged for 2 min at 16,000 × g. The supernatant was removed and incubated in a boiling water bath for 10 min, whereas the pellet was resuspended in 100 µl of 2× SDS stop buffer, without dithiothreitol or dye, and sonicated. Protein determinations were made, and samples were diluted with 2× SDS stop buffer, boiled, electrophoresed on SDS-polyacrylamide gels, and immunoblotted as described above.

Microtubule-binding Assay Using Cell Lysates-- The microtubule-binding assay was carried out as described previously with a few modifications (6). Cells were collected and resuspended in 80 mM PIPES/KOH (pH 6.8) and 1 mM CaCl2 and protease and phosphatase inhibitors. Cell suspensions were sonicated briefly on ice and incubated on ice for 15 min. Samples were brought to 1.5 mM EGTA and centrifuged at 100,000 × g for 1 h at 4 °C. Equal amounts of protein lysate were used in each binding assay. Supernatants were adjusted to 1 mM GTP and 10 µM taxol and incubated with taxol-stabilized microtubules (30 µM) prepared from rat brain (56) in a final volume of 30 µl for 10 min at 37 °C. The mixtures were centrifuged through 100 µl of 30% (w/v) sucrose cushions in 80 mM PIPES/KOH containing 1 mM EGTA, 1 mM GTP, and 10 µM taxol, at 100,000 × g for 30 min in an airfuge at room temperature. The supernatant was collected and diluted with 2× SDS stop buffer, and the pellet was resuspended in 50 µl of 2× SDS stop buffer prior to incubation in a boiling water bath for 5 min. The unbound (supernatant) and bound (pellet) fractions were separated by electrophoresis on a 10% SDS-polyacrylamide gel, transferred to nitrocellulose, and immunoblotted as described above.

Microtubule-binding Assay Using Recombinant Tau-- CHO cells were transfected with HA-GSK3beta , HA-GSK3beta -S9A, HA-GSKbeta -R96A, or vector only as the control. To immunoprecipitate the HA-tagged constructs, 400 µg of protein from cellular extracts was incubated with 4 µl of mouse monoclonal HA antibody overnight at 4 °C with gentle agitation followed by incubation with 40 µl of washed protein G-Sepharose for 2 h at 4 °C. The immobilized immune complexes were washed twice with lysis buffer and twice with kinase buffer. The phosphorylation reaction was carried out by mixing the immunoprecipitates with 20 µl of kinase buffer and 0.08 µg/µl recombinant tau protein. The samples were incubated at 30 °C for 1 h with shaking and then spun to pellet the GSK3beta immune complex. Phosphorylated or control tau (100 ng) was diluted in 80 mM PIPES/KOH (pH 6.8), 1.5 mM EGTA. The samples were adjusted to 1 mM GTP and 10 µM taxol and incubated with taxol-stabilized microtubules (20 µM) in a final volume of 30 µl for 10 min at 37 °C. The mixtures were centrifuged through 100 µl of 30% (w/v) sucrose cushions in 80 mM PIPES/KOH containing 1 mM EGTA, 1 mM GTP, and 10 µM taxol, at 100,000 × g for 30 min in an airfuge at room temperature. The supernatant and pellet were collected and processed as described above.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Wild Type and GSK3beta -R96A Phosphorylate Tau Differentially-- To determine whether GSK3beta differentially phosphorylates tau when the phosphate-binding pocket of GSK3beta is disrupted, cells were transfected with tau alone or with tau and HA-GSK3beta , HA-GSK3beta -R96A, or HA-GSK3beta -S9A. Lysates were collected and immunoblotted with the phosphate-independent tau antibodies Tau5/5A6, AT180, which recognizes tau when Thr-231 is phosphorylated (a primed site), PHF-1, which recognizes tau when Ser-396/404 are phosphorylated (unprimed sites), a GSK3beta antibody, or a beta -actin antibody. In the absence of exogenous GSK3beta tau migrated as a doublet that was not recognized by either AT180 or PHF-1 (Fig. 1). Co-expression of either the wild type or mutant GSK3beta resulted in a significant decrease in the mobility of tau; however in the presence of HA-GSK3beta or HA-GSK3beta -S9A tau migrated as a distinct doublet. In contrast, in the presence of HA-GSK3beta -R96A, tau always presented as a blurred band(s); two distinct tau bands were never observed (also see Fig. 5B). This differential migration of tau in the presence of HA-GSK3beta -R96A compared with HA-GSK3beta or HA-GSK3beta -S9A is likely because of the differential phosphorylation of tau by HA-GSK3beta -R96A. Expression of either HA-GSK3beta or HA-GSK3beta -S9A with tau resulted in a robust increase in AT180 immunoreactivity and to a lesser extent increased PHF-1 staining. In contrast to these findings, expression of HA-GSK3beta -R96A resulted in a large increase in PHF-1 immunoreactivity and only a minimal increase in AT180 immunoreactivity (Fig. 1). In all cases wild type and mutant GSK3beta were expressed at similar levels (Fig. 1). These results suggest that tau is both a primed and unprimed substrate of GSK3beta .


View larger version (71K):
[in this window]
[in a new window]
 
Fig. 1.   GSK3beta phosphorylates tau at both primed and unprimed sites. CHO cells were transiently transfected with tau alone or tau and either HA-GSK3beta (GSK3beta ), HA-GSK3beta -S9A (S9A), or HA-GSK3beta -R96A (R96A). HA-GSK3beta -S9A and HA-GSK3beta -R96A were expressed at similar levels compared with wild type HA-GSK3beta . The phospho-independent antibodies Tau5/5A6 show total tau levels in the transfected cells were approximately the same for all conditions. Tau5/5A6 immunoblotting revealed that the expression of the GSK3beta constructs reduced the electrophoretic mobility of tau significantly, indicating an increase in phosphorylation. In cells overexpressing HA-GSK3beta or HA-GSK3-S9A AT180 immunoreactivity (primed site, phosphorylated Thr-231) was increased significantly; in contrast, expression of HA-GSK3beta -R96A resulted in significantly less AT180 immunoreactivity. Expression of HA-GSK3beta or HA-GSK3-S9A also increased PHF-1 immunoreactivity (unprimed sites, phosphorylated Ser-396/404), but expression of HA-GSK3beta -R96A resulted in a much greater increase in tau phosphorylation at this epitope. Actin blots are included to show equal protein loading for all the samples.

GSK3beta -R96A Phosphorylates Recombinant Tau Efficiently-- The in vitro activity of the different GSK3beta constructs toward primed and unprimed substrates was examined. Cells were transfected with HA-GSK3beta , HA-GSK3beta -R96A, or HA-GSK3beta -S9A immunoprecipitated with the HA antibody and used in the in vitro kinase assays. All the GSK3beta constructs efficiently phosphorylated recombinant tau; however HA-GSK3beta -R96A phosphorylated recombinant tau ~4-fold more than HA-GSK3beta or HA-GSK3beta -S9A (Fig. 2A). In contrast, and as expected (32), HA-GSK3beta -R96A was extremely inefficient in phosphorylating a primed peptide, showing activity that was less than 20% of the activity of HA-GSK3beta or HA-GSK3beta -S9A (Fig. 2B). To determine whether GSK3beta phosphorylates primed tau in a manner similar to the primed peptide, tau was prephosphorylated with cdk5/p25 as described under "Experimental Procedures," prior to use in the in vitro kinase assay. After preparation of the primed or control tau (no ATP in the reaction), no cdk5 was present in the tau fractions as confirmed by immunoblotting for cdk5 (data not shown). Priming of recombinant tau prior to phosphorylation by the GSK3beta constructs demonstrated that HA-GSK3beta -R96A was not as efficient as HA-GSK3beta or HA-GSK3beta -S9A in phosphorylating primed tau (Fig. 2C, left panel). In contrast, HA-GSK3beta -R96A phosphorylated the control, mock phosphorylated tau much more efficiently than HA-GSK3beta or HA-GSK3beta -S9A (Fig. 2C, right panel). These results demonstrate clearly that both in situ and in vitro tau is both a primed and unprimed substrate of GSK3beta .


View larger version (22K):
[in this window]
[in a new window]
 
Fig. 2.   R96A-GSK3beta phosphorylates unprimed tau but does not phosphorylate primed substrates efficiently. HA-GSK3beta (GSK3beta ), HA-GSK3beta -S9A (S9A), or HA-GSKbeta -R96A (R96A) were expressed in cells, immunoprecipitated, and used in in vitro kinase assays. A, HA-GSK3beta -R96A phosphorylates recombinant tau to a significantly greater extent than HA-GSK3beta or HA-GSK3-S9A. Data are presented as a % of HA-GSK3beta activity. Shown is the mean ± S.E. (n = three separate experiments). *, p < 0.05 compared with HA-GSK3beta . B, HA-GSK3beta -R96A phosphorylates a primed peptide to a significantly lesser extent than HA-GSK3beta or HA-GSK3-S9A. Data are presented as a % of HA-GSK3beta activity. Shown is the mean ± S.E. (n = three separate experiments). *, p < 0.05 compared with HA-GSK3beta . C, HA-GSK3beta and HA-GSK3beta -S9A phosphorylate primed tau more efficiently compared with HA-GSK3beta -R96A. To prime tau, tau was prephosphorylated with cdk5/p25 that was immunoprecipitated from cells in which cdk5 and p25 were co-expressed (left panel). As a control (unprimed tau), tau was incubated with the cdk5/p25 immunoprecipitate but in the absence of ATP (right panel). The panels below each graph show the autoradiographs for the experiment. The data were expressed as a percent of HA-GSK3beta activity and are representative of results obtained from two to three separate experiments. These findings demonstrate clearly that priming of tau with cdk5/p25 diminishes the ability of HA-GSK3beta -R96A to phosphorylate tau.

Tau Phosphorylated at a Primed Site Is Only Present in the Soluble Fraction-- To determine whether there is a differential distribution of tau phosphorylated at primed (AT180) and unprimed (PHF-1) sites, cells were transfected with tau alone or tau with one of the GSK3beta constructs, and the detergent-insoluble cytoskeleton was separated from the detergent-soluble fraction. These results (Fig. 3) demonstrate clearly that tau phosphorylated at primed sites (AT180) is only present in the soluble fractions, whereas tau phosphorylated at unprimed sites (PHF-1) is present in both the soluble and insoluble fractions.


View larger version (60K):
[in this window]
[in a new window]
 
Fig. 3.   Tau that is phosphorylated at AT180 (a primed site) is in the soluble fraction. CHO cells were transiently transfected with tau alone or tau and HA-GSK3beta (GSK3beta ), HA-GSK3beta -S9A (S9A), or HA-GSK3beta -R96A (R96A). Cell lysates were separated into cytoskeletal and soluble fractions as described under "Experimental Procedures." Insoluble cytoskeletal (Insol) and soluble (Sol) fractions were electrophoresed and immunoblotted with indicated antibodies. These data demonstrate that tau phosphorylated at the primed epitope AT180 is only present in the soluble fractions, whereas PHF-1 immunoreactivity (unprimed site) is distributed equally between the cytoskeletal and soluble fractions in cells that were transfected with the GSK3beta constructs. Further, AT180 immunoreactivity in cells transfected with HA-GSK3beta -R96A was substantially less than in cells transfected with HA-GSK3beta or HA-GSK3beta -S9A, whereas PHF-1 immunoreactivity was greater.

Primed Phosphorylation Sites of Tau Regulate the Intracellular Localization of Tau-- The next experiment was to determine how GSK3beta -mediated phosphorylation of tau at primed and unprimed sites regulates the association of tau with the cytoskeleton. Cells were transfected with tau alone or with tau and one of the GSK3beta constructs, and the cells were fractionated, and the distribution of tau between the soluble and insoluble fractions was determined (Fig. 4). Co-expression of HA-GSK3beta or HA-GSK3beta -S9A with tau increased the amount of tau in the soluble fraction compared with what was observed in cells transfected with tau alone, indicating that GSK3beta changed the binding affinity of tau for the cytoskeleton/microtubules (Fig. 4). In contrast co-expression of HA-GSK3beta -R96A with tau did not result in an obvious increase in soluble tau levels (Fig. 4). These data suggest that phosphorylation of tau at primed sites may regulate the association of tau with microtubules, whereas GSK3beta -mediated phosphorylation at unprimed sites does not significantly impact tau-microtubule interactions.


View larger version (33K):
[in this window]
[in a new window]
 
Fig. 4.   Phosphorylation of tau at primed sites results in increased tau levels in the soluble fraction. CHO cells were transiently transfected with tau alone or tau and HA-GSK3beta (GSK3beta ), HA-GSK3beta -S9A (S9A), or HA-GSK3beta -R96A (R96A). Cell lysates were separated into cytoskeletal insoluble (Insol) and soluble (Sol) fractions as described under "Experimental Procedures." A, representative immunoblots showing that expression of either HA-GSK3beta or HA-GSK3beta -S9A increases the amount of tau in the soluble fraction. In contrast expression of HA-GSK3beta -R96A does not increase soluble tau levels significantly compared with that observed in cells transfected with tau alone. B, quantitative data demonstrating the increase in soluble tau in cells transfected with HA-GSK3beta or HA-GSK3beta -S9A but not with HA-GSK3beta -R96A compared with cells transfected with tau only (control).

Phosphorylation of Tau at Unprimed Sites by GSK3beta -R96A Does Not Decrease Microtubule Binding-- To further determine the functional significance of tau phosphorylation by GSK3beta at primed and unprimed sites, a microtubule sedimentation assay was performed. High speed supernatants from cells transfected with tau alone or tau and HA-GSK3beta , HA-GSK3beta -R96A, or HA-GSK3beta -S9A were incubated with taxol-stabilized microtubules, and the amount of tau bound to the microtubules in the pellet and the amount of tau that remained unbound was measured. In the absence of GSK3beta , all the tau was in the microtubule-bound pellet. In contrast, when tau was co-expressed with HA-GSK3beta or HA-GSK3beta -S9A a significant amount of tau was observed in the unbound fraction and was recognized by AT180 (Fig. 5A). Interesting, no PHF-1 immunoreactivity was observed in the unbound fractions. Further, co-expression of tau and HA-GSK3beta -R96A did not result in an increase in unbound tau even though there was a significant increase in PHF-1 immunoreactivity in the bound fraction. Fig. 5B shows that the expression of tau and GSK3beta was equivalent in all conditions. These results indicate that phosphorylation of tau by GSK3beta at primed sites is necessary to decrease the affinity of tau for microtubules, whereas phosphorylation at unprimed sites, such as PHF-1, does not significantly effect tau-microtubule interactions.


View larger version (44K):
[in this window]
[in a new window]
 
Fig. 5.   Phosphorylation of tau by GSK3beta at primed sites results in decreased microtubule binding. CHO cells were transiently transfected with tau alone or tau and HA-GSK3beta (GSK3beta ), HA-GSK3beta -S9A (S9A), or HA-GSK3beta -R96A (R96A), and high speed supernatants from the cells were used in a microtubule-binding assay. A, tau is presented in soluble unbound fraction when it was phosphorylated by HA-GSK3beta or HA-GSK3beta -S9A. Taxol-stabilized microtubules were added to the high speed supernatants, the microtubules were pelleted, and the distribution of tau between the microtubule pellet (Bound) and supernatant (Unbound) was determined by immunoblotting with several tau antibodies. These data demonstrate that tau phosphorylated by GSK3beta -R96A remains bound to the microtubules. In contrast, tau phosphorylated by HA-GSK3beta , and to a greater extent GSK3beta -S9A, shifted into the unbound supernatant. Further, AT180 immunoreactivity was present only in the unbound fractions. PHF-1 immunoreactivity was present only in the microtubule-bound fractions. B, total tau and GSK3beta expression levels, as well as the phosphorylation state of tau, were evaluated in the high speed supernatants prior to use in the microtubule-binding assay. These data show that tau and the GSK3beta constructs were all expressed at similar levels.

To further confirm that the phosphorylation of tau at primed sites plays an important role in regulating the interaction of tau with microtubules, recombinant tau was phosphorylated with immunoprecipitated HA-GSK3beta , HA-GSK3beta -S9A, or HA-GSK3beta -R96A or with immunoprecipitates from vector-transfected cells. The phosphorylated recombinant tau was then used in a microtubule-binding assay, and the amount of bound and free tau was determined. These results (Fig. 6) again demonstrate that phosphorylation of tau by HA-GSK3beta or HA-GSK3beta -S9A increased the amount of unbound tau compared with controls, whereas tau phosphorylation by HA-GSK3beta -R96A did not increase the level of unbound tau.


View larger version (22K):
[in this window]
[in a new window]
 
Fig. 6.   In vitro assay demonstrating that phosphorylation of tau at primed sites by GSK3beta decreases microtubule binding by tau. CHO cells were transiently transfected HA-GSK3beta (GSK3beta ), HA-GSK3beta -S9A (S9A), HA-GSK3beta -R96A (R96A), or vector only (-). Immunoprecipitations were carried out using an HA antibody, and the precipitates were used to phosphorylate recombinant tau. A microtubule-binding assay was carried out using the phosphorylated recombinant tau and taxol-stabilized microtubules, and the bound and unbound fractions were immunoblotted for the presence of tau (Tau5/5A6) or tubulin. These results demonstrate that phosphorylation of tau in vitro by HA-GSK3beta or HA-GSK3beta -S9A decreases the association of tau with microtubule, whereas phosphorylation with HA-GSK3beta -R96A does not alter tau-microtubule interactions significantly.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The aim of this study was to gain insight into the site-specific tau phosphorylation by GSK3beta and to determine how phosphorylation of specific epitopes on tau affects its function. Our results clearly demonstrate that GSK3beta phosphorylates tau on both primed and unprimed sites; however it is the phosphorylation of tau at the primed epitopes that decreases tau-microtubule interactions.

It has been demonstrated unequivocally that GSK3beta phosphorylates tau in situ; however most studies have focused the phosphorylation of unprimed sites such as PHF-1, Tau-1, and AT8 (25, 28, 57-59), although in a transgenic mouse model that expressed both human tau and GSK3beta -S9A an increase in AT180 immunoreactivity was noted (59). In vitro it has been demonstrated that AT180 recognition of tau requires Thr-231 to be phosphorylated, and GSK3beta can phosphorylate tau on this site only when Ser-235 is already phosphorylated (53). Therefore, AT180 recognizes a primed GSK3beta epitope. In situ we have shown that disruption of the priming phosphate-binding pocket in GSK3beta by making the R96A mutation (32, 44) impairs the ability of GSK3beta to phosphorylate tau at the AT180 epitope significantly, confirming the in vitro findings. Further, priming of recombinant tau by prephosphorylating it with cdk5/p25 (41, 42) results in a decrease in tau phosphorylation by the GSK3beta -R96A mutant compared with wild type GSK3beta and GSK3beta with the S9A mutation. Interestingly, GSK3beta and GSK3beta -S9A phosphorylated tau to a similar extent; however GSK3beta -R96A phosphorylated recombinant tau much more efficiently than both GSK3beta and GSK3beta -S9A. These data indicate that the enhancement of tau phosphorylation by the GSK3beta -R96A mutant is not because of the inability of GSK3beta -R96A to be inhibited by the pseudosubstrate of the phosphorylated N-terminal (32, 44). In addition, tau phosphorylation at the non-primed PHF-1 epitope was much greater when cells were co-transfected with HA-GSK3beta -R96A compared with HA-GSK3beta or HA-GSK3beta -S9A. The reason for the enhancement in non-primed tau phosphorylation by the GSK-R96A mutant is unknown, but may be because of an increase in the accessibility of tau to the active site. However, the R96A mutation of GSK3beta did not affect phosphorylation of axin or beta -catenin (32).

GSK3beta is a constitutively active kinase that is inactivated by Ser-9 phosphorylation. Engagement of signaling pathways that activate Akt results in GSK3beta Ser-9 phosphorylation and down-regulation of GSK3beta activity. In addition, other protein kinases such as protein kinase C and mitogen-activated protein kinase-activated protein kinase 1 can phosphorylate Ser-9 on GSK3beta and down-regulate its activity (31). In almost all experiments in this study, GSK3beta -S9A showed slightly, but not significantly, more activity than GSK3beta . The likely reason for this observation is that all measures were done under basal conditions and not in the presence of signals that would activate Akt, and therefore the effects of the S9A mutation on GSK3beta activity were not prominent.

There is good evidence that in situ GSK3beta -mediated tau phosphorylation decreases the affinity of tau for microtubules. For example, microtubule depolymerization in response to colchicine treatment was greater in cells transfected with tau and GSK3beta compared with cells transfected with just tau (57, 60), and cells co-transfected with tau and GSK3beta exhibited a reduction in microtubule bundling compared with cells transfected with tau alone (26). Further, in mice transgenic for GSK3beta -S9A and tau increased tau phosphorylation occurred, as well a reduction in the axonopathy that was observed in the mice that just overexpressed human tau (59). The reduction in the axonopathy in response to increased expression of GSK3beta -S9A is likely because of the fact that the increase in tau phosphorylation resulted in a decrease in tau-microtubule interactions, which thus alleviated the inhibition in axonal transport because of tau overexpression (3, 59). Although it is clear that tau is phosphorylated by GSK3beta on numerous sites, the contribution of these different sites to the regulation of tau function in situ has not been explored thoroughly. In this study we show that although GSK3beta -R96A phosphorylates tau in situ at non-primed sites efficiently, and this results in a decrease in the electrophoretic mobility of tau, this did not result in an increase in the amount of free, non-microtubule-bound tau. This is in contrast to wild type GSK3beta or GSK3beta -S9A, which did cause an increase in the levels of unbound tau. Further, AT180 immunoreactivity was only found in the soluble or unbound fraction, indicating that phosphorylation within this epitope and/or at other primed sites may play an important role in regulating the interaction of tau with microtubules. In contrast, PHF-1 immunoreactivity was found exclusively in the bound fractions (Fig. 5A), indicating that phosphorylation of tau at this epitope and/or at other unprimed GSK3beta sites plays less of a role in regulating tau-microtubule interaction. The finding that GSK3beta phosphorylation of primed sites on tau may play a more significant role in regulating the function of tau than unprimed sites is quite intriguing given the fact that the majority of GSK3beta substrates are primed (35). Additionally, recent data have shown that beta -catenin, which was believed previously to be an unprimed substrate of GSK3beta , is actually primed by casein kinase Ialpha (61). Further, different substrates of GSK3beta require different priming protein kinases, such as protein kinase A for cAMP-response element-binding protein and casein kinase II for glycogen synthase (31) and of course casein kinase Ialpha for beta -catenin (61). Therefore one can speculate that the most functionally relevant GSK3beta -mediated tau phosphorylation events are at primed epitopes and that perhaps protein kinase(s) like cdk5/p25 may play an essential role in regulating GSK3beta -mediated tau phosphorylation (41, 42). Indeed, GSK3beta and cdk5/p35[p25] co-purify together with tau and microtubules and were referred to originally as tau protein kinase I and II, respectively (62). A dual kinase system for the regulation of tau phosphorylation by GSK3beta would give a high degree of control for GSK3beta substrate selectivity and provide for the needed regulation of tau function in the cell. Further studies are required to fully elucidate the role of GSK3beta -mediated tau phosphorylation at both primed and unprimed sites and how these site-specific phosphorylation events affect tau function.

    ACKNOWLEDGEMENTS

We thank Dr. L. Binder and Dr. P. Davies for generous antibody gifts, and Dr. J. Woodgett, Dr. M. Hutton, and Dr. L.-H. Tsai for generous gifts of the constructs.

    FOOTNOTES

* This work was supported by National Institutes of Health Grant NS35060 and by a grant from the Alzheimer's Disease Association.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger Supported by a fellowship from the John Douglas French Alzheimer's Foundation.

§ To whom correspondence should be addressed: Dept. of Psychiatry, 1720 7th Ave. S., SC1061, University of Alabama at Birmingham, School of Medicine, Birmingham, AL 35294-0017. Tel.: 205-934-2465; Fax: 205-934-3709; E-mail: gvwj@uab.edu.

Published, JBC Papers in Press, October 29, 2002, DOI 10.1074/jbc.M206236200

    ABBREVIATIONS

The abbreviations used are: cdk5, cyclin-dependent protein kinase 5; GSK3beta , glycogen synthase kinase 3beta ; CHO, Chinese hamster ovary; HA, hemagglutinin; PIPES, 1,4-piperazinediethanesulfonic acid.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Goedert, M., Spillantini, M. G., Potier, M. C., Ulrich, J., and Crowther, R. A. (1989) EMBO J. 8, 393-399[Abstract]
2. Lee, G., Cowan, N., and Kirschner, M. (1988) Science 239, 285-288[Medline] [Order article via Infotrieve]
3. Ebneth, A., Godemann, R., Stamer, K., Illenberger, S., Trinczek, B., and Mandelkow, E. (1998) J. Cell Biol. 143, 777-794[Abstract/Free Full Text]
4. Trinczek, B., Ebneth, A., Mandelkow, E. M., and Mandelkow, E. (1999) J. Cell Sci. 112, 2355-2367[Abstract/Free Full Text]
5. Brandt, R., Leger, J., and Lee, G. (1995) J. Cell Biol. 131, 1327-1340[Abstract]
6. Maas, T., Eidenmuller, J., and Brandt, R. (2000) J. Biol. Chem. 275, 15733-15740[Abstract/Free Full Text]
7. Lee, G., Newman, S. T., Gard, D. L., Band, H., and Panchamoorthy, G. (1998) J. Cell Sci. 111, 3167-3177[Abstract/Free Full Text]
8. Klein, C., Kramer, E. M., Cardine, A. M., Schraven, B., Brandt, R., and Trotter, J. (2002) J. Neurosci. 22, 698-707[CrossRef][Medline] [Order article via Infotrieve]
9. Layfield, R., Fergusson, J., Aitken, A., Lowe, J., Landon, M., and Mayer, R. J. (1996) Neurosci. Lett. 209, 57-60[CrossRef][Medline] [Order article via Infotrieve]
10. Hashiguchi, M., Sobue, K., and Paudel, H. K. (2000) J. Biol. Chem. 275, 25247-25254[Abstract/Free Full Text]
11. Sontag, E., Nunbhakdi-Craig, V., Lee, G., Bloom, G. S., and Mumby, M. C. (1996) Neuron 17, 1201-1207[Medline] [Order article via Infotrieve]
12. Sontag, E., Nunbhakdi-Craig, V., Lee, G., Brandt, R., Kamibayashi, C., Kuret, J., White, C. L., III, Mumby, M. C., and Bloom, G. S. (1999) J. Biol. Chem. 274, 25490-25498[Abstract/Free Full Text]
13. Drubin, D. G., and Kirschner, M. W. (1986) J. Cell Biol. 103, 2739-2746[Abstract]
14. Cleveland, D. W., Hwo, S. Y., and Kirschner, M. W. (1977) J. Mol. Biol. 116, 207-225[Medline] [Order article via Infotrieve]
15. Weingarten, M. D., Lockwood, A. H., Hwo, S. Y., and Kirschner, M. W. (1975) Proc. Natl. Acad. Sci. U. S. A. 72, 1858-1862[Abstract]
16. Jameson, L., Frey, T., Zeeberg, B., Dalldorf, F., and Caplow, M. (1980) Biochemistry 19, 2472-2479[Medline] [Order article via Infotrieve]
17. Lindwall, G., and Cole, R. D. (1984) J. Biol. Chem. 259, 5301-5305[Abstract/Free Full Text]
18. Bramblett, G. T., Goedert, M., Jakes, R., Merrick, S. E., Trojanowski, J. Q., and Lee, V. M. (1993) Neuron 10, 1089-1099[Medline] [Order article via Infotrieve]
19. Busciglio, J., Lorenzo, A., Yeh, J., and Yankner, B. A. (1995) Neuron 14, 879-888[Medline] [Order article via Infotrieve]
20. Brandt, R., Lee, G., Teplow, D. B., Shalloway, D., and Abdel-Ghany, M. (1994) J. Biol. Chem. 269, 11776-11782[Abstract/Free Full Text]
21. Litersky, J. M., Johnson, G. V., Jakes, R., Goedert, M., Lee, M., and Seubert, P. (1996) Biochem. J. 316, 655-660[Medline] [Order article via Infotrieve]
22. Drewes, G., Ebneth, A., Preuss, U., Mandelkow, E. M., and Mandelkow, E. (1997) Cell 89, 297-308[Medline] [Order article via Infotrieve]
23. Ahlijanian, M. K., Barrezueta, N. X., Williams, R. D., Jakowski, A., Kowsz, K. P., McCarthy, S., Coskran, T., Carlo, A., Seymour, P. A., Burkhardt, J. E., Nelson, R. B., and McNeish, J. D. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 2910-2915[Abstract/Free Full Text]
24. Patrick, G. N., Zukerberg, L., Nikolic, M., de la Monte, S., Dikkes, P., and Tsai, L. H. (1999) Nature 402, 615-622[CrossRef][Medline] [Order article via Infotrieve]
25. Lovestone, S., Reynolds, C. H., Latimer, D., Davis, D. R., Anderton, B. H., Gallo, J. M., Hanger, D., Mulot, S., Marquardt, B., Stabel, S., et al.. (1994) Curr. Biol. 4, 1077-1086[Medline] [Order article via Infotrieve]
26. Wagner, U., Utton, M., Gallo, J. M., and Miller, C. C. (1996) J. Cell Sci. 109, 1537-1543[Abstract/Free Full Text]
27. Brownlees, J., Irving, N. G., Brion, J. P., Gibb, B. J., Wagner, U., Woodgett, J., and Miller, C. C. (1997) Neuroreport 8, 3251-3255[Medline] [Order article via Infotrieve]
28. Hong, M., and Lee, V. M. (1997) J. Biol. Chem. 272, 19547-19553[Abstract/Free Full Text]
29. Utton, M. A., Vandecandelaere, A., Wagner, U., Reynolds, C. H., Gibb, G. M., Miller, C. C., Bayley, P. M., and Anderton, B. H. (1997) Biochem. J. 323, 741-747[Medline] [Order article via Infotrieve]
30. Woodgett, J. R. (1990) EMBO J. 9, 2431-2438[Abstract]
31. Grimes, C. A., and Jope, R. S. (2001) Prog. Neurobiol. 65, 391-426[CrossRef][Medline] [Order article via Infotrieve]
32. Frame, S., Cohen, P., and Biondi, R. M. (2001) Mol. Cell 7, 1321-1327[CrossRef][Medline] [Order article via Infotrieve]
33. Hart, M. J., de los Santos, R., Albert, I. N., Rubinfeld, B., and Polakis, P. (1998) Curr. Biol. 8, 573-581[Medline] [Order article via Infotrieve]
34. Rubinfeld, B., Albert, I., Porfiri, E., Fiol, C., Munemitsu, S., and Polakis, P. (1996) Science 272, 1023-1026[Abstract]
35. Harwood, A. J. (2001) Cell 105, 821-824[CrossRef][Medline] [Order article via Infotrieve]
36. Plyte, S. E., Hughes, K., Nikolakaki, E., Pulverer, B. J., and Woodgett, J. R. (1992) Biochim. Biophys. Acta 1114, 147-162[CrossRef][Medline] [Order article via Infotrieve]
37. Cohen, P., and Frame, S. (2001) Nat. Rev. Mol. Cell. Biol. 2, 769-776[CrossRef][Medline] [Order article via Infotrieve]
38. Hagen, T., Di, Daniel, E., Culbert, A. A., and Reith, A. D. (2002) J. Biol. Chem. 277, 23330-23335[Abstract/Free Full Text]
39. Hanger, D. P., Hughes, K., Woodgett, J. R., Brion, J. P., and Anderton, B. H. (1992) Neurosci. Lett. 147, 58-62[CrossRef][Medline] [Order article via Infotrieve]
40. Mandelkow, E. M., Drewes, G., Biernat, J., Gustke, N., Van Lint, J., Vandenheede, J. R., and Mandelkow, E. (1992) FEBS Lett. 314, 315-321[CrossRef][Medline] [Order article via Infotrieve]
41. Ishiguro, K., Shiratsuchi, A., Sato, S., Omori, A., Arioka, M., Kobayashi, S., Uchida, T., and Imahori, K. (1993) FEBS Lett. 325, 167-172[CrossRef][Medline] [Order article via Infotrieve]
42. Sengupta, A., Wu, Q., Grundke-Iqbal, I., Iqbal, K., and Singh, T. J. (1997) Mol. Cell. Biochem. 167, 99-105[CrossRef][Medline] [Order article via Infotrieve]
43. Hughes, K., Nikolakaki, E., Plyte, S. E., Totty, N. F., and Woodgett, J. R. (1993) EMBO J. 12, 803-808[Abstract]
44. Dajani, R., Fraser, E., Roe, S. M., Young, N., Good, V., Dale, T. C., and Pearl, L. H. (2001) Cell 105, 721-732[CrossRef][Medline] [Order article via Infotrieve]
45. Stambolic, V., and Woodgett, J. R. (1994) Biochem. J. 303, 701-704[Medline] [Order article via Infotrieve]
46. Cross, D. A., Alessi, D. R., Cohen, P., Andjelkovich, M., and Hemmings, B. A. (1995) Nature 378, 785-789[CrossRef][Medline] [Order article via Infotrieve]
47. ter Haar, E., Coll, J. T., Austen, D. A., Hsiao, H. M., Swenson, L., and Jain, J. (2001) Nat. Struct. Biol. 8, 593-596[CrossRef][Medline] [Order article via Infotrieve]
48. Zhang, J., Luan, C.-H., Chou, K.-C., and Johnson, G. V. (2002) Proteins 48, 447-453[CrossRef][Medline] [Order article via Infotrieve]
49. Johnson, G. V., Seubert, P., Cox, T. M., Motter, R., Brown, J. P., and Galasko, D. (1997) J Neurochem 68, 430-433[Medline] [Order article via Infotrieve]
50. Carmel, G., Mager, E. M., Binder, L. I., and Kuret, J. (1996) J. Biol. Chem. 271, 32789-32795[Abstract/Free Full Text]
51. Kosik, K. S., Orecchio, L. D., Binder, L., Trojanowski, J. Q., Lee, V. M., and Lee, G. (1988) Neuron 1, 817-825[Medline] [Order article via Infotrieve]
52. Illenberger, S., Zheng-Fischhofer, Q., Preuss, U., Stamer, K., Baumann, K., Trinczek, B., Biernat, J., Godemann, R., Mandelkow, E. M., and Mandelkow, E. (1998) Mol. Biol. Cell 9, 1495-1512[Abstract/Free Full Text]
53. Goedert, M., Jakes, R., Crowther, R. A., Cohen, P., Vanmechelen, E., Vandermeeren, M., and Cras, P. (1994) Biochem. J. 301, 871-877[Medline] [Order article via Infotrieve]
54. Otvos, L., Jr., Feiner, L., Lang, E., Szendrei, G. I., Goedert, M., and Lee, V. M. (1994) J. Neurosci. Res. 39, 669-673[Medline] [Order article via Infotrieve]
55. Watcharasit, P., Bijur, G. N., Zmijewski, J. W., Song, L., Zmijewska, A., Chen, X., Johnson, G. V., and Jope, R. S. (2002) Proc. Natl. Acad. Sci. U. S. A. 99, 7951-7955[Abstract/Free Full Text]
56. Davis, P. K., and Johnson, G. V. (1999) J. Biol. Chem. 274, 35686-35692[Abstract/Free Full Text]
57. Lovestone, S., Hartley, C. L., Pearce, J., and Anderton, B. H. (1996) Neuroscience 73, 1145-1157[CrossRef][Medline] [Order article via Infotrieve]
58. Lucas, J. J., Hernandez, F., Gomez-Ramos, P., Moran, M. A., Hen, R., and Avila, J. (2001) EMBO J. 20, 27-39[Abstract/Free Full Text]
59. Spittaels, K., Van den Haute, C., Van Dorpe, J., Geerts, H., Mercken, M., Bruynseels, K., Lasrado, R., Vandezande, K., Laenen, I., Boon, T., Van Lint, J., Vandenheede, J., Moechars, D., Loos, R., and Van Leuven, F. (2000) J. Biol. Chem. 275, 41340-43149[Abstract/Free Full Text]
60. Sang, H., Lu, Z., Li, Y., Ru, B., Wang, W., and Chen, J. (2001) Neurosci. Lett. 312, 141-144[CrossRef][Medline] [Order article via Infotrieve]
61. Liu, C., Li, Y., Semenov, M., Han, C., Baeg, G. H., Tan, Y., Zhang, Z., Lin, X., and He, X. (2002) Cell 108, 837-847[Medline] [Order article via Infotrieve]
62. Imahori, K., and Uchida, T. (1997) J. Biochem. (Tokyo) 121, 179-188[Abstract]


Copyright © 2003 by The American Society for Biochemistry and Molecular Biology, Inc.